BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, May 29, 2026
Home » Topics » Conferences

Conferences
Conferences RSS Feed RSS

Toilets could be the next big health device: Medical Korea 2025

March 20, 2025
By Marian (YoonJee) Chu
Seung-min Park, professor at Nanyang Technological University and cofounder of Kanaria Health, is working to manufacture smart bidets that can capture biomarker data from urine and stool automatically and enable continuous monitoring.
Read More
Dermatologic

NOA-104 ameliorates atopic dermatitis in the preclinical setting

March 20, 2025
Atopic dermatitis (AD) is mainly triggered by immune dysregulation, barrier dysfunction and inflammation propagation, and chronic itching increases the susceptibility to infections.
Read More
Muscular dystrophy
Neurology/psychiatric

Insmed reports preclinical data on INS-1201 for DMD

March 20, 2025
Investigators from Insmed Inc. have presented new preclinical data on the efficacy of their adenoviral vector (AAV9)-based gene therapy INS-1201 for the treatment of Duchenne muscular dystrophy (DMD).
Read More
Neurology/psychiatric

DMD base editing candidate shows safety and efficacy in preclinical models

March 20, 2025
At this week’s Muscular Dystrophy Association Clinical and Scientific Conference in Dallas, researchers from Suzhou Genassist Therapeutics Co. Ltd. presented preclinical data for GEN-6050X (ss.AAV9.oTAM and ss.AAV9.hE50-sgRNA).
Read More
3D cross-section illustration of muscle anatomy
Musculoskeletal

Epirium Bio’s first-in-class 15-PGDH inhibitor restores muscle strength in aged mice

March 19, 2025
Sarcopenia is an age-related condition in which muscle mass and strength decrease, leading to reduced overall physical performance. As fast-twitch muscle fibers are more impacted by age-related decline, strategies aimed at enhancing the regeneration and functionality of these fibers are essential to prevent the progression of sarcopenia.
Read More
Ocular

Nonclinical analysis of the hyperthermic effect of SJP-0132

March 19, 2025
Researchers from Senju Pharmaceutical Co. Ltd. presented results from preclinical studies that assessed the hyperthermic effects of SJP-0132, a selective antagonist of transient receptor potential vanilloid 1 (TRPV1), which is currently awaiting approval in Japan as an ophthalmic treatment to alleviate the signs and symptoms of dry eye disease.
Read More
Dermatologic

TCR-Nck modulation holds promise in autoimmune skin disorders

March 18, 2025
In atopic dermatitis, psoriasis and other dermatologic diseases, T cells lose tolerance to self-antigens, triggering the autoimmune response that leads to abnormal skin cell proliferation and inflammation. The use of Nck modulators may help correct dysregulated T-cell receptor (TCR) signaling, potentially restoring immune tolerance and reducing subsequent inflammatory responses.
Read More
Red coronavirus with long shadow
Infection

Long COVID science is progressing, though therapies have not yet followed

March 18, 2025
By Anette Breindl
In 2020, the Conference on Retroviruses and Opportunistic Infections (CROI) was the first scientific conference to move from in-person to virtual due to the COVID-19 pandemic. On the fifth anniversary of the virtual conference, and the pandemic, some of those earliest COVID-19 patients have still not recovered.
Read More
Coronavirus variants
Infection

ALG-097558 confirmed as an effective pan-coronavirus strategy

March 17, 2025
Although safe and effective vaccines for SARS-CoV-2 have been successfully developed, there are currently no therapeutic approaches available for treating acute infection, particularly for individuals at high risk of severe disease progression, and for preparedness against a potential new coronavirus pandemic.
Read More
Cancer

Combining KAT6A/B inhibitor and retinoic acid shows efficacy in neuroblastoma models

March 17, 2025
Neuroblastoma, an aggressive malignancy originating from neural crest cells, accounts for 15% of cancer-related deaths in children. Treatment strategies include systemic chemotherapy, radiation or immunotherapy with anti-GD2 antibodies, all with severe side effects and long-term toxicity. Retinoic acid (RA) has been shown to promote neuroblastoma growth inhibition while suppressing MYCN oncogene expression. However, its effect is reversible, and tumor regrowth may occur.
Read More
Previous 1 2 … 78 79 80 81 82 83 84 85 86 … 3205 3206 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 29, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 26, 2026
  • Microscopy of a cross-section of mouse skin containing melanoma tumors

    Researchers identify innate immune barrier against melanoma

    BioWorld
    Australian researchers have identified a previously overlooked population of immune cells in the skin that physically restrain melanoma growth by engulfing live...
  • Floating antibody drug conjugates

    TROP2 ADCs progress into first-line for lung, breast cancers

    BioWorld
    Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...
  • Cavalon Therapeutics and Northwestern patent new Cav1.3 blockers

    BioWorld Science
    Cavalon Therapeutics Inc. and Northwestern University have disclosed new voltage-gated calcium channel Cav1.3 blockers potentially useful for the treatment of...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing